Effect of Lipid Nanoparticle Physico-Chemical Properties and Composition on Their Interaction with the Immune System
Pharmaceutics · 26.11.2024 · 16 (12) · 1521
DOI: 10.3390/pharmaceutics16121521 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 26.11.2024. Verfasst von Laura Catenacci und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Sciences, University of Pavia, 27100 Pavia, Italy. Die Arbeit wurde bisher 88-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union, ational Center on Gene Therapy and Drugs Based on RNA Technology.
Abstract (Originalsprache)
Lipid nanoparticles (LNPs) have shown promise as a delivery system for nucleic acid-based therapeutics, including DNA, siRNA, and mRNA vaccines. The immune system plays a critical role in the response to these nanocarriers, with innate immune cells initiating an early response and adaptive immune cells mediating a more specific reaction, sometimes leading to potential adverse effects. Recent studies have shown that the innate immune response to LNPs is mediated by Toll-like receptors (TLRs) and other pattern recognition receptors (PRRs), which recognize the lipid components of the nanoparticles. This recognition can trigger the activation of inflammatory pathways and the production of cytokines and chemokines, leading to potential adverse effects such as fever, inflammation, and pain at the injection site. On the other hand, the adaptive immune response to LNPs appears to be primarily directed against the protein encoded by the mRNA cargo, with little evidence of an ongoing adaptive immune response to the components of the LNP itself. Understanding the relationship between LNPs and the immune system is critical for the development of safe and effective nucleic acid-based delivery systems. In fact, targeting the immune system is essential to develop effective vaccines, as well as therapies against cancer or infections. There is a lack of research in the literature that has systematically studied the factors that influence the interaction between LNPs and the immune system and further research is needed to better elucidate the mechanisms underlying the immune response to LNPs. In this review, we discuss LNPs’ composition, physico-chemical properties, such as size, shape, and surface charge, and the protein corona formation which can affect the reactivity of the immune system, thus providing a guide for the research on new formulations that could gain a favorable efficacy/safety profile.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Drug Sciences, University of Pavia, 27100 Pavia, Italy.
- Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, 27100 Pavia, Italy.
ORCID-Profile: Laura Catenacci, Milena Sorrenti, Sara Perteghella, Marco Peviani, Maria Cristina Bonferoni
Förderung
- European Union
- ational Center on Gene Therapy and Drugs Based on RNA Technology
Zitieren
APA
Catenacci, L., Rossi, R., Sechi, F., Buonocore, D., Sorrenti, M., Perteghella, S., Peviani, M., & Bonferoni, M. C. (2024). Effect of Lipid Nanoparticle Physico-Chemical Properties and Composition on Their Interaction with the Immune System. Pharmaceutics, 16(12), 1521. https://doi.org/10.3390/pharmaceutics16121521
Vancouver
Catenacci L, Rossi R, Sechi F, Buonocore D, Sorrenti M, Perteghella S, et al. Effect of Lipid Nanoparticle Physico-Chemical Properties and Composition on Their Interaction with the Immune System. Pharmaceutics. 2024;16(12):1521. doi:10.3390/pharmaceutics16121521
BibTeX
@article{Catenacci2024,
author = {Catenacci, Laura and Rossi, Rachele and Sechi, Francesca and Buonocore, Daniela and Sorrenti, Milena and Perteghella, Sara and Peviani, Marco and Bonferoni, Maria Cristina},
title = {Effect of Lipid Nanoparticle Physico-Chemical Properties and Composition on Their Interaction with the Immune System},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {12},
pages = {1521},
doi = {10.3390/pharmaceutics16121521}
}
EUVIMED